Industries > Pharma > Checkpoint Inhibitors for Treating Cancer Market Report 2018-2028

Checkpoint Inhibitors for Treating Cancer Market Report 2018-2028

Analysing Prospects for PD-1 Inhibitors, CLTA-4 Inhibitors and Pipeline Drugs

PUBLISHED: 23 April 2018
PAGES: 161
PRODUCT CODE: PHA0303

Clear
WOOCS 2.2.1
DOWNLOAD SAMPLE
SKU: PHA0303 Categories: , , Tags: ,

Checkpoint Inhibitors for Treating Cancer – our new study reveals trends, R&D progress, and predicted revenues
Where is the Checkpoint Inhibitors for Treating Cancer market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2028, assessing data, trends, opportunities and business prospects there.

Discover How to Stay Ahead
Our 161-page report provides 107 tables, charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Checkpoint Inhibitors for Treating Cancer market. See how to exploit the opportunities.

Forecasts to 2028 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2028, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.

Discover sales predictions for the world market and submarkets
Along with revenue prediction for the overall world market, there are forecasts for 3 submarkets and 5 Drugs in the report at a global level, as well as profiles for 14 pipeline drug candidates

Global Checkpoint Inhibitors for Treating Cancer Market by Type
• PD-1 Inhibitors
• CLTA-4 Inhibitors
• Pipeline Drugs

Global Checkpoint Inhibitors for Treating Cancer Market by Drug
• Opdivo (nivolumab)
• Keytruda (pembrolizumab)
• Yervoy (ipilimumab)
• Tecentriq (Atezolizumab)
• Tremelimumab (CP-675,206)

Checkpoint Inhibitors for Treating Cancer Market Report 2018-2028

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 8 major regional/national markets:
• The US
• Japan
• Germany
• The UK
• Italy
• France
• Spain
• Asia-Pacific

The report also includes profiles and for some of the leading companies in the Checkpoint Inhibitors for Treating Cancer market, with a focus on this segment of these companies’ operations.

There will be growth in both established and in developing countries. Our analyses show that the both developed and developing markets, the US, the UK and the APAC region in particular, will continue to achieve high revenue growth to 2028.

Leading companies and the potential for market growth
Overall world revenue for Checkpoint Inhibitors for Treating Cancer will surpass $7.9bn in 2018, our work calculates. We predict strong revenue growth through to 2027.

Our work identifies which organisations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How the Checkpoint Inhibitors for Treating Cancer Market report helps you
In summary, our 161-page report provides you with the following knowledge:
• Revenue forecasts to 2027 for the Checkpoint Inhibitors for Treating Cancer market, with forecasts for 3 submarkets and 5 Drugs, each forecasted at a global level – discover the industry’s prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2028 for 8 key regional and national markets – See forecasts for the Checkpoint Inhibitors for Treating Cancer in Asia-Pacific, the US, Germany, France, the UK, Italy, France, and Japan,
• What stimulates and restrains companies and the market
• Prospects for established firms and those seeking to enter the market
– including company profiles for some of the major companies involved in the Checkpoint Inhibitors for Treating Cancer market

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else
With our newly updated report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions.

Visiongain’s study is for everybody needing commercial analyses for the Checkpoint Inhibitors for Treating Cancer market and leading companies. You will find data, trends and predictions.

Get our report today Checkpoint Inhibitors for Treating Cancer Market Report 2018-2028: Analysing Prospects for PD-1 Inhibitors, CLTA-4 Inhibitors and Pipeline Drugs.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

1. Report Overview

1.1 Global Overview of the Checkpoint Inhibitor Anti-Cancer Treatment Market 2017

1.2 Benefits of This Report

1.3 How This Report Delivers

1.4 Key Questions Answered by This Analytical Report

1.5 Who is This Report For?

1.6 Methods of the Study

1.7 Frequently Asked Questions (FAQ)

1.8 Associated Visiongain Reports

1.9 About Visiongain


2. Introduction to the Checkpoint Inhibitor Anti-Cancer World Market 2017

2.1 Checkpoint Inhibitors: A New Era in Immunotherapy

2.2 Checkpoint Inhibitor Drug Treatments in Oncology


3. Leading Checkpoint Inhibitors: Anti-Cancer Drug Forecasts 2018-2028 and Leading Companies in the World Market

3.1 Leading Checkpoint Inhibitor Anti-Cancer Drug Treatments on the Market in 2017

3.1.1 Yervoy (ipilimumab) – Bristol-Myers Squibb

3.1.1.1 Yervoy: Sales Analysis

3.1.2 Opdivo (nivolumab) – Bristol-Myers Squibb/Ono Pharmaceutical

3.1.2.1 Opdivo: Sales Analysis

3.1.3 Keytruda (pembrolizumab) – Merck & Co.

3.1.3.1 Keytruda: Sales Analysis

3.2 Leading Companies in the Checkpoint Inhibitor Anti-Cancer Treatment Market in 2017

3.2.1 Bristol-Myers Squibb Leads the Market


4. Checkpoint Inhibitor Anti-Cancer Treatment: World Market 2018-2028

4.1 The Global Market for Checkpoint Inhibitor Anti-Cancer Treatments in 2017

4.2 The World Anti-Cancer Checkpoint Inhibitor Market: Revenue Forecasts 2018-2028

4.3 Leading Checkpoint Inhibitor Treatment Submarkets Forecast 2018-2028

4.3.1 The CTLA-4 Inhibitors Submarket Forecast 2018-2028

4.3.2 The PD-1 Inhibitors Submarket Forecast 2018-2028

4.3.3 Changing Market Shares: PD-1 Inhibitors Will Lead the Market

4.3.4 Market Dynamics of the Checkpoint Inhibitor Anti-Cancer Treatment Market 2018-2028

4.3.4.1 Drivers of the Checkpoint Inhibitor Anti-Cancer Treatment Market

4.3.4.1.1 Increasing Prevalence of Cancer

4.3.4.1.2 Increasing Adoption Of Immunotherapy

4.3.4.1.3 Increasing Cancer Awareness

4.3.4.2 Restraints of the Checkpoint Inhibitor Anti-Cancer Treatment Market

4.3.4.2.1 Expensive Nature of Treatment

4.3.4.2.2 High Attrition Rates

4.3.4.3 Opportunity of the Checkpoint Inhibitor Anti-Cancer Treatment Market

4.3.4.3.1 Increasing Demand Of Checkpoint Inhibitors In Emerging Markets

4.3.4.3.2 Immunotherapy Showing Increased Efficacy Over Chemotherapy

4.3.4.4 Trends of the Checkpoint Inhibitor Anti-Cancer Treatment Market

4.3.4.4.1 Collaborations And Mergers In This Market


5. Leading National Markets for the Checkpoint Inhibitor Anti-Cancer Treatment Market 2018-2028

5.1 Regional Breakdown of the World Checkpoint Inhibitor Anti-Cancer Treatments Market 2018-2028

5.2 World Checkpoint Inhibitor Anti-Cancer Treatment Market: Regional Forecast 2018-2028

5.2.1 How Will Regional Market Shares Change to 2027?

5.3 The US Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2018-2028

5.4 The EU Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2018-2028

5.4.1 Germany: The Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2018-2028

5.4.2 France: The Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2018-2028

5.4.3 Italy: The Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2018-2028

5.4.4 The UK: The Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2018-2028

5.4.5 Spain: The Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2018-2028

5.5 Japan: The Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2018-2028

5.6 The APAC Market: Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2018-2028


6. The Checkpoint Inhibitor Anti-Cancer Treatment Market Pipeline Analysis 2018-2028

6.1 Anti-PD-1 Inhibitors and Anti-PD-L1 Inhibitors

6.1.1 Tecentriq (Atezolizumab)

6.1.2 Pidilizumab (CT-011) – CureTech Ltd

6.1.3 AMP-224 – GSK/Amplimmune

6.1.4 REGN2810 – Regeneron/Sanofi

6.2 CTLA-4 Inhibitors

6.2.1 Tremelimumab (CP-675,206) - AstraZeneca

6.3 LAG-3 (lymphocyte activation gene-3) Inhibitors

6.3.1 IMP321- Prima Biomed

6.3.2 BMS-986016 - Bristol-Myers Squibb

6.3.3 IMP701 – Prima BioMed/Novartis

6.4 KIR Inhibitors

6.4.1 Lirilumab (IPH2102/BMS-986015) – Innate Pharma/Bristol-Myers Squibb

6.5 Anti-NKG2A Inhibitors

6.5.1 IPH2201 – Innate Pharma/AstraZeneca/MedImmune

6.6 Other Checkpoint Inhibitors

6.6.1 VISTA Inhibitors

6.6.1.1 CA-170 – Curis Inc/Aurigene Discovery Technologies

6.6.1.2 NLG919 – NewLink Genetics

6.6.1.3 INCB024360 – Incyte/Roche

6.6.2 A2aR Inhibitors

6.6.2.1 HTL-1071 – AstraZeneca/Heptares


7. Qualitative Analysis of the Checkpoint Inhibitor Anti-Cancer Treatment Market 2018-2028

7.1 SWOT Analysis of the Checkpoint Inhibitor Anti-Cancer Treatment Market 2018-2028

7.2 Strengths and Weaknesses of the Checkpoint Inhibitor Anti-Cancer Treatment Market

7.2.1 A Novel Treatment Method that Harnesses the Immune System’s Vast Potential

7.2.2 Pricing of the Treatments Will Attract Companies

7.2.3 Cost of Treatment Will Restrain Market Access

7.2.4 Side Effects May Prohibit Growth

7.3 Opportunities and Threats for the Checkpoint Inhibitor Anti-Cancer Treatment Market

7.3.1 Biomarkers Pave the Way for Optimum Utility

7.3.2 Combination Therapies Are Achieving Superior Results

7.3.3 The Cost Burden of Expensive Drug Treatments on Healthcare Systems

7.3.4 Crowding of the Market with Similar Products


8. Company Profiles

8.1 AstraZeneca Plc.

8.1.1 Company Overview

8.1.2 Key Developments

8.2 Bristol-Myers Squibb Co.

8.2.1 Company Overview

8.2.2 Key Developments

8.3 Celldex Therapeutics Inc.

8.3.1 Company Overview

8.3.2 Key Developments

8.4 Incyte Corporation

8.4.1 Company Overview

8.4.2 Key Developments

8.5 Merck & Co., Inc.

8.5.1 Company Overview

8.5.2 Key Developments

8.6 Novartis Ag

8.6.1 Company Overview

8.6.2 Key Developments

8.7 Pfizer Inc.

8.7.1 Company Overview

8.7.2 Key Developments

8.8 Roche Holding Ag

8.8.1 Company Overview

8.8.2 Key Developments


9. Conclusions

9.1 The Global Checkpoint Inhibitor Anti-Cancer Treatment Market: Current World Outlook

9.1.1 Driver for Growth: A Robust and Innovative Pipeline for the Checkpoint Inhibitors Anti-Cancer Treatment Market to 2028

9.2 Leading National Markets for the Checkpoint Inhibitor Anti-Cancer Treatment Market 2018-2028: The US and EU Will Retain Their Lead

9.3 The Future of the Checkpoint Inhibitor Anti-Cancer Treatment Market


Visiongain Report Sales Order Form

About Visiongain

Visiongain report evaluation form

Associated Visiongain Reports


List of Figures

Figure 1.1 Global Checkpoint Inhibitor Anti-Cancer Treatment Market Segmentation Overview, 2017

Figure 3.1 Yervoy (ipilimumab): Historical Sales ($bn), 2013-2016

Figure 3.2 Yervoy Forecast, Revenue ($bn), 2017-2028

Figure 3.3 Opdivo Forecast, Revenue ($bn), 2017-2028

Figure 3.4 Keytruda Forecast, Revenue ($bn),2017-2028

Figure 3.5 Leading Companies in the Checkpoint Inhibitor Anti-Cancer Market by Revenue: Market Shares, 2017

Figure 4.1 Global Market for Anti-Cancer Checkpoint Inhibitors: Market Shares by Class (%), 2017

Figure 4.2 Global Market Forecast for Anti-Cancer Checkpoint Inhibitors by Class: Market Sizes ($bn), 2017-2028

Figure 4.3 Global Market for Anti-Cancer Checkpoint Inhibitors: Market Shares by Class (%), 2017

Figure 4.4 Global Market Forecast for CTLA-4 Inhibitors: Revenue ($bn), 2017-2028

Figure 4.5 Global Market Forecast for PD-1 Inhibitors: Revenue ($bn), 2017-2028

Figure 4.6 Global Market for Anti-Cancer Checkpoint Inhibitors: Market Shares by Class (%), 2023

Figure 4.7 Global Market for Anti-Cancer Checkpoint Inhibitors: Market Shares by Class (%), 2028

Figure 5.1 Regional and National Breakdown of the Checkpoint Inhibitor Cancer Treatment Market: Market Shares (%), 2017

Figure 5.2 Forecast of Regional and National Checkpoint Inhibitor Cancer Treatment Markets: Market Sizes ($bn), 2017-2028

Figure 5.3 Forecast of Regional and National Checkpoint Inhibitor Cancer Treatment Markets: Market Shares (%), 2023

Figure 5.4 Forecast of Regional and National Checkpoint Inhibitor Cancer Treatment Markets: Market Shares (%), 2028

Figure 5.5 Forecast of the US Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), 2017-2028

Figure 5.6 Forecast of the EU Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), 2017-2028

Figure 5.7 EU Market for the Checkpoint Inhibitor Cancer Treatment by Leading Country (%), 2017

Figure 5.8 Forecast of the EU Checkpoint Inhibitor Cancer Treatment Market, Market Sizes ($bn), 2017-2028

Figure 5.9 Forecast of the German Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), 2017-2028

Figure 5.10 Forecast of the French Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), 2018-2028

Figure 5.11 Forecast of the Italian Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), 2017-2028

Figure 5.12 Forecast of the UK Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), 2017-2028

Figure 5.13 Forecast of the Spanish Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), 2017-2028

Figure 5.14 Forecast of the Japanese Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), 2017-2028

Figure 5.15 Forecast of the APAC Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), 2017-2028

Figure 6.1 Tecentriq Forecast: Revenue ($bn), 2018-2028

Figure 6.2 Tremelimumab Forecast: Revenue ($bn), 2017-2028

Figure 9.1 Checkpoint Inhibitor Anti-Cancer Drug Treatment Market Forecast by Class: Market Sizes ($bn), 2017-2028

Figure 9.2 Checkpoint Inhibitor Anti-Cancer Treatment Market Forecasts by Region: Market Size ($bn), 2017, 2019, 2023, and 2028


List of Tables

Table 2.1 Main Types of Checkpoint Inhibitors in Development, 2017

Table 3.1 Yervoy (Ipilimumab): Historical Sales ($bn, AGR%), 2013-2016

Table 3.2 Yervoy Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2023

Table 3.3 Yervoy Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2023-2028

Table 3.4 Opdivo Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2023

Table 3.5 Opdivo Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2023-2028

Table 3.6 Keytruda Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2023

Table 3.7 Keytruda Forecast, Revenue ($bn), Annual Growth (%), CAGR (%),2023-2028

Table 3.8 Leading Companies in the Checkpoint Inhibitor Treatment Market: Revenue ($bn), Market Share (%), 2017

Table 4.1 Global Market for Anti-Cancer Checkpoint Inhibitors: Revenues ($bn) and Market Shares (%) by Class, 2017

Table 4.2 Checkpoint Inhibitors by Revenue ($bn), 2017

Table 4.3 Checkpoint Inhibitors by Revenue ($bn), 2018

Table 4.4 Global Market Forecast for Anti-Cancer Checkpoint Inhibitors by Class: Market Sizes ($bn), Annual Growth Rates (%), CAGR (%), 2017-2023

Table 4.5 Global Market Forecast for Anti-Cancer Checkpoint Inhibitors by Class: Market Sizes ($bn), Annual Growth Rates (%), CAGR (%), 2023-2028

Table 4.6 Global Market for Anti-Cancer Checkpoint Inhibitors: Revenues ($bn) and Market Shares (%) by Class, 2017

Table 4.7 Global Market Forecast for CTLA-4 Inhibitors: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2017-2023

Table 4.8 Global Market Forecast for CTLA-4 Inhibitors: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2023-2028

Table 4.9 Global Market Forecast for PD-1 Inhibitors: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2017-2023

Table 4.10 Global Market Forecast for PD-1 Inhibitors: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2023-2028

Table 4.11 Global Market Forecast for Anti-Cancer Checkpoint Inhibitors by Class: Market Shares (%), 2017-2023

Table 4.12 Global Market Forecast for Anti-Cancer Checkpoint Inhibitors by Class: Market Shares (%), 2023-2028

Table 5.1 Regional and National Breakdown of the Checkpoint Inhibitor Cancer Treatment Market: Market Sizes ($bn), Market Shares (%), 2017

Table 5.2 Forecast of Regional and National Checkpoint Inhibitor Cancer Treatment Markets: Market Sizes ($bn), Annual Growth (%), CAGRs (%),2017-2023

Table 5.3 Forecast of Regional and National Checkpoint Inhibitor Cancer Treatment Markets: Market Sizes ($bn), Annual Growth (%), CAGRs (%), 2023-2028

Table 5.4 Forecast of Regional and National Checkpoint Inhibitor Cancer Treatment Markets: Market Shares (%), 2017-2023

Table 5.5 Forecast of Regional and National Checkpoint Inhibitor Cancer Treatment Markets: Market Shares (%), 2023-2028

Table 5.6 Forecast of the US Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2017-2023

Table 5.7 Forecast of the US Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2023-2028

Table 5.8 EU Market Shares (%), 2017-2023

Table 5.9 EU Market Shares (%), 2023-2028

Table 5.10 Forecast of the EU Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2017-2023

Table 5.11 Forecast of the EU Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2023-2028

Table 5.12 Forecast of the German Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2017-2023

Table 5.13 Forecast of the German Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2023-2028

Table 5.14 Forecast of the French Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2017-2023

Table 5.15 Forecast of the French Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2023-2028

Table 5.16 Forecast of the Italian Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2017-2023

Table 5.17 Forecast of the Italian Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2023-2028

Table 5.18 Forecast of the UK Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2017-2023

Table 5.19 Forecast of the UK Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2023-2028

Table 5.20 Forecast of the Spanish Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2017-2023

Table 5.21 Forecast of the Spanish Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2023-2028

Table 5.22 Forecast of the Japanese Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2017-2023

Table 5.23 Forecast of the Japanese Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2023-2028

Table 5.24 Forecast of the APAC Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2017-2023

Table 5.25 Forecast of the APAC Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2023-2028

Table 6.1 Selected Combination Therapies for Atezolizumab, 2016

Table 6.2 Tecentriq Forecast: Revenue ($bn), 2017-2022

Table 6.3 Tecentriq Forecast: Revenue ($bn), 2022-2027

Table 6.8 Tremelimumab Forecast: Revenue ($bn), 2017-2028

Table 6.9 Tremelimumab Forecast: Revenue ($bn), 2023-2028

Table 7.1 Strengths and Weaknesses of the Checkpoint Inhibitor Cancer Treatment Market, 2016

Table 7.2 Opportunities and Threats of the Checkpoint Inhibitor Cancer Treatment Market, 2015

Table 8.1 AstraZeneca PLC. Profile 2016 (CEO, Total Company Sales $m, Sales in the Market $m, Net Income / Loss $m, Net Capital Expenditure $m, Strongest Business Region, Business Segment in the Market, HQ, Founded, No. of Employees, Ticker, Website)

Table 8.2:AstraZeneca: Key Developments

Table 8.3 Bristol-Myers Squibb Co. Profile 2016 (CEO, Total Company Sales $m, Sales in the Market $m, Net Income / Loss $m, Net Capital Expenditure $m, Strongest Business Region, Business Segment in the Market, HQ, Founded, No. of Employees, Ticker, Website)

Table 8.4: Bristol-Myers Squibb: Key Developments

Table 8.4: Bristol-Myers Squibb: Key Developments

Table 8.4: Bristol-Myers Squibb: Key Developments

Table 8.5 Celldex Therapeutics Inc. Profile 2016 (CEO, Total Company Sales $m, Sales in the Market $m, Net Income / Loss $m, Net Capital Expenditure $m, Strongest Business Region, Business Segment in the Market, HQ, Founded, No. of Employees, Ticker, Website)

Table 8.6: Celldex Therapeutics: Key Developments

Table 8.7 Incyte Corporation Profile 2016 (CEO, Total Company Sales $m, Sales in the Market $m, Net Income / Loss $m, Net Capital Expenditure $m, Strongest Business Region, Business Segment in the Market, HQ, Founded, No. of Employees, Ticker, Website)

Table 8.8: Incyte: Key Developments

Table 8.8: Incyte: Key Developments

Table 8.9 Merck & Co., Inc. Profile 2016 (CEO, Total Company Sales $m, Sales in the Market $m, Net Income / Loss $m, Net Capital Expenditure $m, Strongest Business Region, Business Segment in the Market, HQ, Founded, No. of Employees, Ticker, Website)

Table 8.10: Merck & Co.: Key Developments

Table 8.10: Merck & Co.: Key Developments

Table 8.11 Novartis AG Profile 2016 (CEO, Total Company Sales $m, Sales in the Market $m, Net Income / Loss $m, Net Capital Expenditure $m, Strongest Business Region, Business Segment in the Market, HQ, Founded, No. of Employees, Ticker, Website)

Table 8.12: Novartis: Key Developments

Table 8.13 Pfizer Inc. Profile 2016 (CEO, Total Company Sales $m, Sales in the Market $m, Net Income / Loss $m, Net Capital Expenditure $m, Strongest Business Region, Business Segment in the Market, HQ, Founded, No. of Employees, Ticker, Website)

Table 8.14: Pfizer: Key Developments

Table 8.15: Roche Holding AG Profile 2016 (CEO, Total Company Sales CHF m, Sales in the Market CHF m, Net Income / Loss CHF m, Net Capital Expenditure CHF m, Strongest Business Region, Business Segment in the Market, HQ, Founded, No. of Employees, Ticker, Website)

Table 8.16: Roche: Key Developments

Table 9.1 Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast by Region: Market Size ($bn), Market Share (%), CAGR (%), 2017, 2019, 2023, and 2028

Table 9.2 Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Forecasts by Class: Market Size ($bn), Market Share (%), CAGR (%), 2017, 2019, 2023, and 2028

Aurigene

4-Antibody AG

Abbott

AbbVie

Adimab

Advaxis

Agenus

AgonOX

Ambrx

Amgen

Amplimmune

AnaptysBio

arGEN-X

Bayer

BeiGene

Bio-Matrix Scientific Group

BioWa

Boehringer Ingelheim

Bristol Myers Squibb

Celgene

Cell Genesys

Celldex Therapeutics

Compugen

CoStim Pharmaceuticals

CureTech

Eddingpharm

Facet Biotech

Five Prime Therapeutics

Gilead BioSciences

GITR /Tolerx

GlaxoSmithKline

HealthCare Ventures

IDM

Immutep

Incyte Corporation

Innate Pharma

iTeos Therapeutics

KAHR Medical

Kyowa Hakko Kirin

Laureate Pharma

Lee's Pharma

Lonza Biologics

MacroGenics

Medarex

MedImmune/AstraZeneca

Medivation

Merck

Merck Serono

Millennium Pharmaceuticals

MolMed S.p.A

MorphoSys

MRC Technology

NewLink Genetics

Novartis

Novo Nordisk

Oncothyreon

Ono Pharmaceutical

Onyx (subsidiary of Amgen)

Orega Biotech

PDL Biopharma

Pfizer

Pierre Fabre

Prima BioMed

Recipharm Cobra Biologics

Regis Technologies

Roche/Genentech

Samsung Biologics

Seattle Genetics

Servier

Sorrento Therapeutics

Spring Bioscience

Tesaro

ToleroTech

Ventana Medical Systems


List of Organizations

Azienda Ospedaliera Universitaria Senese

CRI (Cancer Research Institute)

EMA (European Medicines Agency)

FDA (US Food and Drug Administration)

Georgia Health Sciences University

IGR (Institut Gustav Roussy)

Lankenau Institute for Medical Research (LIMR)

LICR (Ludwig Cancer Research)

Ludwig Cancer Research

Masonic Cancer Center

MHLW (Ministry of Health, Labour, and Welfare)

NHS (National Health Service)

NICE (the National Institute for Health and Care Excellence)

University of California, Berkeley

University of Iowa Pharmaceutical Services

University of Minnesota

University of Texas

WHO (World Health Organization)

Download sample pages

Complete the form below to download your free sample pages for Checkpoint Inhibitors for Treating Cancer Market Report 2018-2028


Download sample pages

Complete the form below to download your free sample pages for Checkpoint Inhibitors for Treating Cancer Market Report 2018-2028


facebookWin a Free Visiongain Pharma report – ‘Like’ our Pharma Facebook page with the link below and enter into our raffle to win a free, unlocked Visiongain report, choosing your relevant report from our reports selection.

Click here to ‘Like’ our Facebook page https://www.facebook.com/V.G.Pharma/

Would you like a free report overview of the report of your choice?

If so, please drop an email to Sara Peerun stating your chosen report title to sara.peerun@visiongain.com

Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
Would you like to get the latest Visiongain pharma reports catalogue?

What are the dynamic growth sectors? where are the regional business opportunities?

Which technologies will prevail and who are the leading companies succeeding in these sectors and why?

If you want definitive answers to business critical questions, discover Visiongain’s full range of business intelligence reports.

If so, please email Sara Peerun on sara.peerun@visiongain.com or call her today on +44 (0) 20 7549 9987

  • Human Microbiome Therapeutics Market 2019-2029
  • Top 20 Urology Companies 2019
  • Global Antidepressant and Anti-Anxiety Drugs Market Forecasts 2019-2029
  • The Top 100 In-Vitro Diagnostics Companies to Watch 2019
  • Global Hypertension Drugs Market 2019-2029
  • The Next Generation Sequencing Market 2019-2029
  • Lyophilisation for Pharmaceuticals: Products and Services 2019-2029
  • Top 25 In Vitro Diagnostics (IVD) Companies 2019
  • Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market 2019-2029
  • Global Biomarkets and Technologies Market 2019-2029
American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Kuwait Pharmaceutical Association
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Generic Medicines Association
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia

Latest Pharma news

“Global Clinical Trial Supply and Logistics market for pharma set to grow to $26bn by 2024” says new Visiongain report

Emerging markets offer many benefits for companies looking to conduct clinical trials, including large patient population and lower trial costs.

18 April 2019

READ

“Global Biosimilar Drugs market set to grow to $57bn by 2023” says new Visiongain report

The biosimilars landscape will likely to undergo great changes in the future as the market starts to mature.

17 April 2019

READ

“Global Drug Discovery Outsourcing market set to grow to $45bn by 2024” says new Visiongain report

A major restraint in the global drug discovery outsourcing market comes from the fact that it is quickly becoming saturated, with many contract research organisations offering poorly differentiated services.

16 April 2019

READ

“Global Dermatological Drugs market set to grow to $36bn by 2024” says new Visiongain report

The dermatological drugs market has in the past been the domain of small and medium-sized pharma companies specialising in dermatology and perhaps a few other therapeutic areas.

15 April 2019

READ

Categories

Category